Oncology ASCO 2023 – Gregory Lubiniecki With its blockbuster checkpoint inhibitor Keytruda, Merck has been a star of the show at many ASCO conferences in recent years.
News FDA experts lukewarm on AZ's anticoagulant antidote Andexxa AstraZeneca is facing some pushback as it tries to upgrade anticoagulant antidote drug Andexaa to full approval in the US
Sales & Marketing Coming soon: The Life Sciences Industry Report 2025 – insigh... Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends
